Please wait...
Latest press release
news
Media
Echosens in the news...
Our most recent press releases
30/03/2011 | EASL 2011: VCTE(TM) Developed by Echosens, the Leading Technique for Evaluation of Liver Disease.
The VCTE(TM) (Vibration Controlled Transient Elastography) from Echosens stood out as a leading technique in the field. It is the only technique able to measure elasticity at a predetermined, controlled frequency (50 Hz), which is essential because elasticity increases as frequency increases.
28/11/2010 | AASLD 2010: Echosens continues to push the boundaries of innovation with CAP™: the first, non-invasive solution for the measurement of hepatic steatosis.
At the 2010 meeting of the American Association for the Study of Liver Disease (AASLD), which took place in Boston from October 29 to November 2, Echosens, a pioneer and major player in the field of non-invasive hepatic diagnostics, presented its latest research and development focus: the CAP™ (Controlled Attenuation Parameter).
15/04/2010 | EASL 2010: To Broaden Access to Examinations, Echosens, a World Leader in Elastography, Presents an Addition to Its Fibroscan® Product Line.
On the occasion of the 2010 edition of the European Association for the Study of the Liver (EASL) conference, Echosens, a pioneer and major player in the field of non-invasive hepatology diagnosis, introduces its new research and development focus with the launching of the latest addition to the Echosens product line, the FibroScan® 402.
05/02/2010 | FibroScan® expands its application to NASH / NAFLD patients.
To meet the urgent need for non invasive alternative two teams of experts from France (head by Pr de Ledinghen) and Hong Kong (head by Pr Wong) demonstrate that the FibroScan® can be the revolutionary tool that the clinical practitioners dream of.
05/02/2010 | A highly representative FibroScan® presence at the GASL Congress.
A highly representative FibroScan® presence at the GASL Congress.
30/10/2009 | Echosens is a major world actor in Elastography.
Last month, at the Institute of Electrical and Electronics Engineers (IEEE) Conference in Rome, Echosens presented a series of papers and posters on its research work, including Viscosity and Micro-Elastography. Some of its new applications will also be presented during the American Association for the Study of Liver Disease (AASLD) in Boston, from October 30 to November 3, 2009.
09/09/2009 | Canada approves FibroScan and its 3 probes.
The FibroScan® with all its 3 probes has received market clearance in Canada. This occurs right after the worldwide launch of the XL Probe.
30/06/2009 | Echosens launches the XL Probe.
Now with the new XL probe, all patients can be included even obese thanks to a complete software, hardware and training package of innovation & optimization.
03/11/2008 | New global solution for measuring hepatic fibrosis to obese patients presented by Echosens at AASLD.
During the annual meeting of the AASLD (American Association for the Study of Liver Diseases) in San Francisco, Echosens has launched a dedicated device for measuring hepatic fibrosis in patients with BMI (Body Mass Index) > 30 kg/m2.
Press kit
AN INTERNATIONAL PRESENCE
Echosens is present in more than 70 countries worldwide, through a network of 29 distributors. Echosens has subsidiaries in Germany, Spain and China, and an agency in China. FibroScan® received approval in Brazil in 2010, and in Japan in early 2011.
Need information? Contact us by e-mail at communication@echosens.com
